Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

Rambam Health Care Campus

Status and phase: Unknown; Phase 4

Conditions: NIDDM

Treatments: Drug: candesartan

Study type: Interventional

Funder types: Other

Identifiers

NCT00192803

ACE2.CTIL

Details and patient eligibility

About

This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan.

This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Non-smokers
• Type II DM diagnosed patients
• Blood pressure < 135/90
• Serum HbA1C > 7%
• Serum creatinine < 1mg%
• Urine microalbumin < 300 mg/day
• Body mass index (BMI) < 35 kg/m2

Exclusion criteria

• Insulin-dependent diabetic patients
• Patient with persistent microalbuminuria
• Patient with history of severe hypertension
• Congestive heart failure
• Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications.
• Patient with major hepatic disease

Trial design

Primary purpose: Educational/Counseling/Training

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)